Skip to main content
. 2015 Jun 24;3(5):1029–1034. doi: 10.3892/mco.2015.586

Figure 3.

Figure 3.

Progression-free and overall survival of patients with or without grade ≥2 skin rash within each observation period. The progression-free survival (PFS) and overall survival (OS) curves of the patients who did and did not experience grade ≥2 skin rash within 2, 4, 6 and 8 weeks and over the entire treatment course following cetuximab initiation. Dashed line, patients with severe skin rash; and solid line, patients without severe skin rash.